Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a report published on Friday.

Other equities research analysts have also recently issued reports about the company. Raymond James reiterated an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Friday. Finally, Scotiabank raised their target price on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Stock Down 0.1 %

Shares of Agios Pharmaceuticals stock opened at $44.83 on Friday. The company has a 50-day simple moving average of $44.62 and a two-hundred day simple moving average of $42.32. Agios Pharmaceuticals has a twelve month low of $20.40 and a twelve month high of $53.28. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of 3.95, a price-to-earnings-growth ratio of 0.45 and a beta of 0.75.

Insider Activity

In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Brian Goff sold 11,091 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter worth about $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 363 shares during the period. CWM LLC grew its holdings in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, North Star Asset Management Inc. acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at approximately $216,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.